Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-Year follow-up of a prospective controlled study

Journal of Clinical Oncology

Volumn 23, Issue 31, 2005, Pages 8025-8032

  Fan, Helen G Mar ^a   Houédé Tchen, Nadine ^a   Yi, Qi Long ^a   Chemerynsky, Irene ^a   Downie, Fiona P ^a   Sabate, Kathryn ^a   Tannock, Ian F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RELAPSE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; ENDOCRINE DISEASE; FATIGUE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HORMONAL THERAPY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SCREENING TEST; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; MENOPAUSE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT; RISK FACTOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; COGNITION DISORDERS; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MENOPAUSE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS;

EID: 32944466310     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.6550     Document Type: Article

References (28)

1. Knobf MT: Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer. J Clin Oncol 4:678-684, 1986
2. Wieneke MH, Dienst ER: Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 4:61-66, 1995
3. van Dam FS, Schagen SB, Muller MJ, et al: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210-218, 1998
4. Broeckel JA, Jacobsen PB, Horton J, et al: Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 16:1689-1696, 1998
5. Schagen SB, van Dam FS, Muller MJ, et al: Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma Cancer 85:640-650, 1999
6. Brezden CB, Phillips KA, Abdolell M, et al: Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695-2701, 2000
7. Bower JE, Ganz PA, Desmond KA, et al: Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. J Clin Oncol 18:743-753, 2000
8. Ganz PA, Greendale GA, Petersen L, et al: Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial. J Natl Cancer Inst 92:1054-1064, 2000
9. Ahles TA, Saykin AJ, Furstenberg CT, et al: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485-493, 2002
10. de Jong N, Candel MJ, Schouten HC, et al: Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy. Ann Oncol 15:896-905, 2004
11. Tchen N, Juffs HG, Downie FP, et al: Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21:4175-4183, 2003
12. Yellen SB, Cella DF, Webster K, et al: Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13:63-74, 1997
13. Failowfield LJ, Leaity SK, Howell A, et al: Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 55:189-199, 1999
14. T4. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
15. Faust D, Fogel BS: The development and initial validation of a sensitive bedside cognitive screening test. J Nerv Ment Dis 177:25-31, 1989
16. Fogel BS: The high sensitivity cognitive screen. Int Psychogeriatr 3:273-288, 1991
17. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198, 1975
18. Conners CK, Barta F Jr: Transfer of information from touch to vision in brain-injured and emotionally disturbed children. J Nerv Ment Dis 145:138-141, 1967
19. Patat A, Alberini H, Bonhomme D, et al: Effects of tiapride on electroencephalograms and cognitive functions in the elderly. Int Clin Psychopharmacol 14:199-208, 1999
20. Army Individual Test Battery, Manual of Directions and Scoring. Washington, DC, War Department, Adjutant General's Office, 1944
21. Zl. Diggle PJ, Liang KY, Zeger SL: Analysis of Longitudinal Data. New York, NY, Oxford University Press, 1994
22. Z2. Schwartz CE, Sprangers MA: Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Soc Sci Med 48:1531-1548, 1999
23. Phillips KA, Bernhard J: Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. J Natl Cancer Inst 95:190-197, 2003
24. Anderson-Hanley C, Sherman ML, Riggs R, et al: Neuropsychological effects of treatments for adults with cancer: A meta-analysis and review of the literature. J Int Neuropsychol Soc 9:967-982, 2003
25. Wefel JS, Lena R, Theriault RL, et al: The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer 100:2292-2299, 2004
26. Castellon SA, Ganz PA, Bower JE, et al: Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955-969, 2004
27. Goodwin PJ, Ennis M, Pritchard KI, et al: Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17:2365-2370, 1999
28. Loprinzi CL, Kugler JW, Sloan JA, et al: Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial. Lancet 356:2059-2063, 2000